keyword
https://read.qxmd.com/read/38634185/identification-of-functional-and-diverse-circulating-cancer-associated-fibroblasts-in-metastatic-castration-na%C3%A3-ve-prostate-cancer-patients
#1
JOURNAL ARTICLE
Richell Booijink, Leon W M M Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal
In prostate cancer (PCa), cancer-associated fibroblasts (CAFs) promote tumor progression, drug resistance, and metastasis. Although circulating tumor cells are studied as prognostic and diagnostic markers, little is known about other circulating cells and their association with PCa metastasis. Here, we explored the presence of circulating CAFs (cCAFs) in metastatic castration-naïve prostate cancer (mCNPC) patients. cCAFs were stained with fibroblast activation protein (FAP), epithelial cell adhesion molecule (EpCAM), and receptor-type tyrosine-protein phosphatase C (CD45), then FAP+ EpCAM- cCAFs were enumerated and sorted using fluorescence-activated cell sorting...
April 17, 2024: Molecular Oncology
https://read.qxmd.com/read/38633791/overexpression-of-fibroblast-activation-protein-fap-in-stroma-of-proliferative-inflammatory-atrophy-pia-and-primary-adenocarcinoma-of-the-prostate
#2
Fernanda Caramella-Pereira, Qizhi Zheng, Jessica L Hicks, Sujayita Roy, Tracy Jones, Martin Pomper, Lizamma Antony, Alan K Meeker, Srinivasan Yegnasubramanian, Angelo M De Marzo, W Nathaniel Brennen
Fibroblast activation protein (FAP) is a serine protease upregulated at sites of tissue remodeling and cancer that represents a promising therapeutic and molecular imaging target. In prostate cancer, studies of FAP expression using tissue microarrays are conflicting, such that its clinical potential is unclear. Furthermore, little is known regarding FAP expression in benign prostatic tissues. Here we demonstrated, using a novel iterative multiplex IHC assay in standard tissue sections, that FAP was nearly absent in normal regions, but was increased consistently in regions of proliferative inflammatory atrophy (PIA)...
April 5, 2024: medRxiv
https://read.qxmd.com/read/38633044/doxorubicin-loaded-thermostable-nanoarchaeosomes-a-next-generation-drug-carrier-for-breast-cancer-therapeutics
#3
JOURNAL ARTICLE
Kaviya Vijayalakshmi Babunagappan, Abirami Seetharaman, Subastri Ariraman, Poornima Budime Santhosh, Julia Genova, Natasa Poklar Ulrih, Swathi Sudhakar
Breast cancer has a poor prognosis due to the toxic side effects associated with high doses of chemotherapy. Liposomal drug encapsulation has resulted in clinical success in enhancing chemotherapy tolerability. However, the formulation faces severe limitations with a lack of colloidal stability, reduced drug efficiency, and difficulties in storage conditions. Nanoarchaeosomes (NA) are a new generation of highly stable nanovesicles composed of the natural ether lipids extracted from archaea. In our study, we synthesized and characterized the NA, evaluated their colloidal stability, drug release potential, and anticancer efficacy...
April 16, 2024: Nanoscale advances
https://read.qxmd.com/read/38631570/exploring-the-association-of-postn-cancer-associated-fibroblasts-with-triple-negative-breast-cancer
#4
JOURNAL ARTICLE
Shuangyan Lin, Miaoni Zhou, Liying Cheng, Zhifeng Shuai, Mingyuan Zhao, Ruixia Jie, Qun Wan, Fang Peng, Qiang Shu, Shiping Ding
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis. Cancer-associated fibroblasts (CAFs) play a critical role in regulating TNBC tumor development. This study aimed to identify and characterize a specific subtype of CAFs associated with TNBC. Initially, using high-throughput bulk transcriptomic data in two cohorts, we identified three CAF-related subtypes (CS1, CS2, CS3) in TNBC samples. These three CAFs subtypes were closely linked to the tumor microenvironment. The CS1 subtype exhibited a relatively immune-rich microenvironment and a favourable prognosis, whereas the CS3 subtype displayed an immune-deprived tumor microenvironment and an unfavourable prognosis...
April 15, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38630893/small-extracellular-vesicles-promote-stiffness-mediated-metastasis
#5
JOURNAL ARTICLE
Alexandra Sneider, Ying Liu, Bartholomew Starich, Wenxuan Du, Praful R Nair, Carolyn Marar, Najwa Faqih, Gabrielle E Ciotti, Joo Ho Kim, Sejal Krishnan, Salma Ibrahim, Muna Igboko, Alexus Locke, Daniel M Lewis, Hanna Hong, Michelle N Karl, Raghav Vij, Gabriella C Russo, Estibaliz Gómez-de-Mariscal, Mehran Habibi, Arrate Muñoz-Barrutia, Luo Gu, T S Karin Eisinger-Mathason, Denis Wirtz
Tissue stiffness is a critical prognostic factor in breast cancer and is associated with metastatic progression. Here we show an alternative and complementary hypothesis of tumor progression whereby physiological matrix stiffness affects the quantity and protein cargo of small EVs produced by cancer cells, which in turn aid cancer cell dissemination. Primary patient breast tissue produces significantly more EVs from stiff tumor tissue than soft tumor adjacent tissue. EVs released by cancer cells on matrices that model human breast tumors (25 kPa; stiff EVs) feature increased adhesion molecule presentation (ITGα2β1, ITGα6β4, ITGα6β1, CD44) compared to EVs from softer normal tissue (0...
April 17, 2024: Cancer Res Commun
https://read.qxmd.com/read/38630822/spatiotemporal-architecture-of-immune-cells-and-cancer-associated-fibroblasts-in-high-grade-serous-ovarian-carcinoma
#6
JOURNAL ARTICLE
Alexander M Xu, Marcela Haro, Ann E Walts, Ye Hu, Joshi John, Beth Y Karlan, Akil Merchant, Sandra Orsulic
High-grade serous ovarian carcinoma (HGSOC), the deadliest form of ovarian cancer, is typically diagnosed after it has metastasized and often relapses after standard-of-care platinum-based chemotherapy, likely due to advanced tumor stage, heterogeneity, and immune evasion and tumor-promoting signaling from the tumor microenvironment. To understand how spatial heterogeneity contributes to HGSOC progression and early relapse, we profiled an HGSOC tissue microarray of patient-matched longitudinal samples from 42 patients...
April 19, 2024: Science Advances
https://read.qxmd.com/read/38630781/safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-from-a-phase-i-study-of-simlukafusp-alfa-fap-il2v-in-advanced-metastatic-solid-tumors
#7
JOURNAL ARTICLE
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E Rodriguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero
PURPOSE: Simlukafusp alfa (FAP-IL2v), a tumor-targeted immunocytokine, comprising an interleukin-2 variant moiety with abolished CD25 binding fused to human immunoglobulin G1, is directed against fibroblast activation protein-α. This phase I, open-label, multicenter, dose-escalation and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of FAP-IL2v in patients with advanced/metastatic solid tumors. METHODS: Participants received FAP-IL2v intravenously once weekly...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38629816/head-to-head-comparison-of-68-ga-fapi-pet-ct-with-18-f-fdg-pet-ct-in-primary-and-metastatic-lesions-of-gastric-tumor-a-systematic-review-and-meta-analysis
#8
JOURNAL ARTICLE
Cailiang Gao, Huiting Liu, Lirong Zhou, Wei Huang, Xue Liu
OBJECTIVE: Our study aims to head to head compare the application of gallium-68-fibroblast activation proteininhibitor (68 Ga-FAPI) positron emission tomography/computed tomography (PET/CT) and fluorine-18-fluorodeoxyglucose (18 F-FDG) PET/CT in primary and metastatic lesions of gastric tumor to determine the superior diagnostic tool. MATERIALS AND METHODS: A systematic search, up to March 31, 2023, across PubMed, Embase, and Cochrane Library databases utilized a data-specific Boolean logic strategy...
April 18, 2024: Hellenic Journal of Nuclear Medicine
https://read.qxmd.com/read/38628214/pomegranate-peel-bioactivities-as-antimicrobial-and-cytotoxic-agents
#9
JOURNAL ARTICLE
Lubna F Abu-Niaaj, Hala I Al-Daghistani, Ibrahim Katampe, Bashaer Abu-Irmaileh, Yasser K Bustanji
This is a comparative study to evaluate the effectiveness of six pomegranate peel extracts (PPEs) as antibacterial and antiproliferative agents. The Six PPEs were prepared using four solvent systems and each filtrate was concentrated to a gummy material to be used in the evaluation. The well-diffusion method was used to evaluate their antimicrobial activity against bacteria typically associated with food spoilage: Escherichia coli , Pseudomonas aeruginosa , Salmonella typhimurium , Listeria monocytogenes , Staphylococcus epidermidis , Staphylococcus aureus , and three Bacillus species ...
April 2024: Food Science & Nutrition
https://read.qxmd.com/read/38627854/integration-of-single-cell-rna-seq-and-bulk-rna-seq-data-to-construct-and-validate-a-cancer-associated-fibroblast-related-prognostic-signature-for-patients-with-ovarian-cancer
#10
JOURNAL ARTICLE
Liang Shen, Aihua Li, Jing Cui, Haixia Liu, Shiqian Zhang
BACKGROUND: To establish a prognostic risk profile for ovarian cancer (OC) patients based on cancer-associated fibroblasts (CAFs) and gain a comprehensive understanding of their role in OC progression, prognosis, and therapeutic efficacy. METHODS: Data on OC single-cell RNA sequencing (scRNA-seq) and total RNA-seq were collected from the GEO and TCGA databases. Seurat R program was used to analyze scRNA-seq data and identify CAFs clusters corresponding to CAFs markers...
April 16, 2024: Journal of Ovarian Research
https://read.qxmd.com/read/38627714/a-hypoxia-glycolysis-lactate-related-gene-signature-for-prognosis-prediction-in-hepatocellular-carcinoma
#11
JOURNAL ARTICLE
Xiaodan Qin, Huiling Sun, Shangshang Hu, Yuqin Pan, Shukui Wang
BACKGROUND: Liver cancer ranks sixth in incidence and third in mortality globally and hepatocellular carcinoma (HCC) accounts for 90% of it. Hypoxia, glycolysis, and lactate metabolism have been found to regulate the progression of HCC separately. However, there is a lack of studies linking the above three to predict the prognosis of HCC. The present study aimed to identify a hypoxia-glycolysis-lactate-related gene signature for assessing the prognosis of HCC. METHODS: This study collected 510 hypoxia-glycolysis-lactate genes from Molecular Signatures Database (MSigDB) and then classified HCC patients from TCGA-LIHC by analyzing their hypoxia-glycolysis-lactate genes expression...
April 16, 2024: BMC Medical Genomics
https://read.qxmd.com/read/38627168/potential-therapeutic-targets-of-fibrosis-in-inflammatory-rheumatic-diseases
#12
REVIEW
Jiang Su, Julianna Desmarais, Cong-Qiu Chu, Jing Zhu
Fibrosis is commonly associated with chronic rheumatic diseases, and causes substantial morbidity and mortality. Treatment of fibrosis is extremely challenging but is badly needed, as approved antifibrotic therapies fibrosis do not halt its progression, which will be discussed with a focus on pulmonary fibrosis. Findings from recent studies indicate several therapeutic targets for treating fibrosis. Interleukin-11 is emerging as a fibrogenic cytokine whose activity can be blocked with neutralizing monoclonal antibodies...
April 15, 2024: Best Practice & Research. Clinical Rheumatology
https://read.qxmd.com/read/38627014/acquisition-duration-optimization-using-visual-grading-regression-in-68-ga-fapi-46-pet-imaging-of-oncologic-patients
#13
JOURNAL ARTICLE
Ted Nilsson, Pawel Rasinski, Örjan Smedby, Siri Af Burén, Ernesto Sparrelid, J Matthias Löhr, Thuy A Tran, August Blomgren, Antonios Tzortzakakis, Rimma Axelsson, Maria Holstensson
Fibroblast activation protein is a promising target for oncologic molecular imaging with radiolabeled fibroblast activation protein inhibitors (FAPI) in a large variety of cancers. However, there are yet no published recommendations on how to set up an optimal imaging protocol for FAPI PET/CT. It is important to optimize the acquisition duration and strive toward an acquisition that is sufficiently short while simultaneously providing sufficient image quality to ensure a reliable diagnosis. The aim of this study was to evaluate the feasibility of reducing the acquisition duration of [68 Ga]FAPI-46 imaging while maintaining satisfactory image quality, with certainty that the radiologist's ability to make a clinical diagnosis would not be affected...
April 16, 2024: Journal of Nuclear Medicine Technology
https://read.qxmd.com/read/38626632/fibroblast-growth-factor-6
#14
JOURNAL ARTICLE
Jennelle Smith, Loydie A Jerome-Majewska
Fibroblast Growth Factor 6 (FGF6), also referred to as HST2 or HBGF6, is a member of the Fibroblast Growth Factor (FGF), the Heparin Binding Growth Factor (HBGF) and the Heparin Binding Secretory Transforming Gene (HST) families. The genomic and protein structure of FGF6 is highly conserved among varied species, as is its expression in muscle and muscle progenitor cells. Like other members of the FGF family, FGF6 regulates cell proliferation, differentiation, and migration. Specifically, it plays key roles in myogenesis and muscular regeneration, angiogenesis, along with iron transport and lipid metabolism...
April 10, 2024: Differentiation; Research in Biological Diversity
https://read.qxmd.com/read/38626388/modelling-structural-elements-and-functional-responses-to-lymphatic-delivered-cues-in-a-murine-lymph-node-on-a-chip
#15
JOURNAL ARTICLE
Corrado Mazzaglia, Hafsa Munir, Iek M Le, Magda Gerigk, Yan Yan Shery Huang, Jacqueline D Shields
Lymph nodes (LNs) are organs of the immune system, critical for maintenance of homeostasis and initiation of immune responses, yet there are few models that accurately recapitulate LN functions in vitro. To tackle this issue, an engineered murine LN (eLN) was developed, replicating key cellular components of the mouse LN; incorporating primary murine lymphocytes, fibroblastic reticular cells (FRCs), and lymphatic endothelial cells (LECs). T and B cells compartments are incorporated within the eLN that mimic LN cortex and paracortex architectures...
April 16, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38626060/the-role-of-the-fibroblast-in-barrett-s-esophagus-and-esophageal-adenocarcinoma
#16
JOURNAL ARTICLE
Huili Zhu, Ramon U Jin
PURPOSE OF REVIEW: Barrett's esophagus (BE) is the number one risk factor for developing esophageal adenocarcinoma (EAC), a deadly cancer with limited treatment options that has been increasing in incidence in the US. In this report, we discuss current studies on the role of mesenchyme and cancer-associated fibroblasts (CAFs) in BE and EAC, and we highlight translational prospects of targeting these cells. RECENT FINDINGS: New insights through studies using single-cell RNA sequencing (sc-RNA seq) have revealed an important emerging role of the mesenchyme in developmental signaling and cancer initiation...
April 12, 2024: Current Opinion in Gastroenterology
https://read.qxmd.com/read/38625505/cancer-associated-fibroblasts-derived-exosomal-mettl3-promotes-the-proliferation-invasion-stemness-and-glutaminolysis-in-non-small-cell-lung-cancer-cells-by-eliciting-slc7a5-m6a-modification
#17
JOURNAL ARTICLE
Yafeng Fan, Yanling Yu
Cancer-associated fibroblasts (CAFs) can promote the crosstalk between cancer cells and tumor microenvironment by exosomes. METTL3-mediated N6-methyladenine (m6A) modification has been proved to promote the progression of non-small cell lung cancer (NSCLC). Here, we focused on the impacts of CAFs-derived exosomes and METTL3-mediated m6A modification on NSCLC progression. Functional analyses were conducted using Cell Counting Kit-8, EdU, colony formation, sphere formation and transwell assays, respectively. Glutamine metabolism was evaluated by detecting glutamate consumption, and the production of intercellular glutamate and α-ketoglutarate (α-KG)...
April 16, 2024: Human Cell
https://read.qxmd.com/read/38621748/tumor-organoids-the-era-of-personalized-medicine
#18
REVIEW
Natalia V Rassomakhina, Alexandra Yu Ryazanova, Astemir R Likhov, Sergey A Bruskin, Liliya G Maloshenok, Victoria V Zherdeva
The strategies of future medicine are aimed to modernize and integrate quality approaches including early molecular-genetic profiling, identification of new therapeutic targets and adapting design for clinical trials, personalized drug screening (PDS) to help predict and individualize patient treatment regimens. In the past decade, organoid models have emerged as an innovative in vitro platform with the potential to realize the concept of patient-centered medicine. Organoids are spatially restricted three-dimensional clusters of cells ex vivo that self-organize into complex functional structures through genetically programmed determination, which is crucial for reconstructing the architecture of the primary tissue and organs...
January 2024: Biochemistry. Biokhimii︠a︡
https://read.qxmd.com/read/38621585/targeting-cellular-senescence-as-a-therapeutic-vulnerability-in-gastric-cancer
#19
JOURNAL ARTICLE
Haigang Geng, Chen Huang, Lei Xu, Yangyang Zhou, Zhongyi Dong, Yiqing Zhong, Qian Li, Chen Yang, Shaozhuo Huang, Weixin Liao, Yuxuan Lin, Zhicheng Liu, Qing Li, Zizhen Zhang, Chunchao Zhu
AIMS: Cellular senescence (CS) represents an intracellular defense mechanism responding to stress signals and can be leveraged as a "vulnerability" in cancer treatment. This study aims to construct a CS atlas for gastric cancer (GC) and uncover potential therapeutics for GC patients. MATERIALS AND METHODS: 38 senescence-associated regulators with prognostic significance in GC were obtained from the CellAge database to construct Gastric cancer-specific Senescence Score (GSS)...
April 13, 2024: Life Sciences
https://read.qxmd.com/read/38619621/cd200-is-overexpressed-in-the-pancreatic-tumor-microenvironment-and-predictive-of-overall-survival
#20
JOURNAL ARTICLE
Jessica Wedig, Shrina Jasani, Debasmita Mukherjee, Hannah Lathrop, Priya Matreja, Timothy Pfau, Liliana D'Alesio, Abigail Guenther, Lexie Fenn, Morgan Kaiser, Molly A Torok, Jake McGue, Gina M Sizemore, Anne M Noonan, Mary E Dillhoff, Bradley W Blaser, Timothy L Frankel, Stacey Culp, Phil A Hart, Zobeida Cruz-Monserrate, Thomas A Mace
Pancreatic cancer is an aggressive disease with a 5 year survival rate of 13%. This poor survival is attributed, in part, to limited and ineffective treatments for patients with metastatic disease, highlighting a need to identify molecular drivers of pancreatic cancer to target for more effective treatment. CD200 is a glycoprotein that interacts with the receptor CD200R and elicits an immunosuppressive response. Overexpression of CD200 has been associated with differential outcomes, depending on the tumor type...
April 15, 2024: Cancer Immunology, Immunotherapy: CII
keyword
keyword
115234
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.